John Taylor, MD
Urology · Kansas City, KSNPI 1003813940
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 51.6% of the total. Reporting peaked in 2019 at $7,732 and has fallen 99.5% since, to $35 in 2025.
Across 23 payments — averaging $391.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- Photocure Inc$3K
- Astrazeneca UK Limited$1K
- Livanova USA, Inc.$215
- Urogen Pharma, Inc.$152
- AstraZeneca$35
- plus $17 from 1 others
Across 34 payments — averaging $4585.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Photocure Inc$156K
What the payments were for
- Consulting fees$4,48450%
- Speaking & faculty fees$2,50028%
- Travel & lodging$94010%
- Food & beverage$1,03512%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $4,645 |
| Photocure Inc | 5 | $2,855 |
| Astrazeneca UK Limited | 1 | $1,074 |
| Livanova USA, Inc. | 5 | $215 |
| Urogen Pharma, Inc. | 1 | $152 |
| AstraZeneca | 1 | $35 |
| Rochester Medical Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cysview$2,634
- JELMYTO$152
- VNS Therapy$111
How this compares
$8,993 in reported general payments places this provider in the 80th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 40 | $700 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $577 |
| Oxybutynin Chloride | 26 | $127 |
| Levofloxacin | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other urology in Kansas City
- Wilson MolinaKansas City$239K
- Bristol WhilesKansas City$163K
- Jeffrey HolzbeierleinKansas City$78K
- Ahmad El-ArabiKansas City$55K
- David DucheneKansas City$33K
- Joshua BroghammerKansas City$24K
- William ParkerKansas City$20K
- Casey KowalikKansas City$8K
- Richard FantusKansas City$7K
- Andrew ArtherKansas City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.